donorderiv
viral
infect
repres
signific
risk
recipi
solid
organ
hematopoiet
stem
cell
transplant
sot
hsct
set
virus
transmit
due
latent
activ
infect
donor
time
donat
rare
donor
infect
acut
transmiss
occur
incub
period
infect
symptom
evid
infect
aris
exampl
donor
transfus
infect
blood
near
time
death
clinic
consequ
infect
transplant
recipi
depend
virul
infect
pathogen
immun
statu
recipi
pathogen
question
level
host
immunosuppress
among
factor
immunocompromis
patient
may
unusu
present
infect
even
organ
low
virul
may
caus
high
morbid
mortal
recipi
routin
donor
screen
place
cytomegaloviru
cmv
epsteinbarr
viru
ebv
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
hepat
b
hbv
hepat
c
hcv
human
immunodefici
viru
hiv
although
posit
donor
test
preclud
organ
transplant
except
hiv
transplant
organ
infect
donor
discret
transplant
center
transplant
surgeon
commonli
recogn
transplanttransmit
pathogen
herpesvirus
eg
hsv
vzv
cmv
ebv
human
herp
viru
hepat
virus
eg
hbv
hcv
retrovirus
eg
human
tcell
leukemia
viru
htlv
although
transmiss
hiv
unusu
given
current
screen
use
nucleic
acid
test
nat
notabl
infect
either
emerg
donor
popul
otherwis
unusu
caus
ill
transplant
patient
mani
pathogen
zoonot
natur
exampl
includ
west
nile
viru
wnv
rabi
lymphocyt
choriomening
viru
lcmv
tabl
wnv
transplantassoci
transmiss
recogn
first
larg
epidem
season
activ
us
four
organ
recipi
develop
infect
common
donor
three
complic
neuroinvas
diseas
febril
ill
associ
donor
contract
infect
blood
transfus
risk
infect
transfus
greatli
reduc
blood
donor
screen
initi
nat
although
rare
breakthrough
infect
still
occur
subsequ
addit
report
transplant
transmiss
donor
like
acquir
infect
mosquito
investig
donor
found
igm
posit
indic
evid
recent
acquisit
infect
viremia
could
detect
nat
wnv
infect
also
suspect
transmit
hsct
mening
enceph
unknown
etiolog
patient
recent
posttranspl
caus
clinician
consid
transplant
transmiss
wnv
although
wnv
neuroinvas
diseas
occur
less
wnv
infect
overal
transplant
patient
acquir
infect
estim
risk
develop
neuroinvas
diseas
compar
gener
popul
four
recipi
kidney
liver
arteri
segment
common
organ
donor
die
enceph
later
diagnos
rabi
enceph
develop
four
recipi
within
day
transplant
associ
delirium
seizur
respiratori
failur
coma
antibodi
rabi
viru
present
three
four
recipi
along
donor
reportedli
bitten
bat
investig
also
outlin
import
care
account
manag
tissu
organassoci
conduit
hospit
investig
sourc
rabi
infect
arteri
segment
recipi
clear
two
separ
occurr
transplant
transmiss
lcmv
also
report
transplant
recipi
abdomin
pain
alter
mental
transplanttransmit
infect
rare
might
difficult
recogn
physician
consid
possibl
particularli
unexplain
neurolog
complic
occur
investig
underscor
challeng
detect
diagnos
infect
occur
recipi
organ
tissu
common
donor
potenti
diseas
transmiss
donor
sourc
may
consid
recipi
evalu
investig
abil
connect
ill
common
organ
donor
facilit
fact
multipl
recipi
hospit
facil
organ
tissu
transplant
becom
common
potenti
risk
diseas
transmiss
may
also
increas
improv
diagnost
assay
donortransmit
infect
increasingli
recogn
although
often
time
impact
infect
well
understood
advent
polymeras
chain
reaction
pcr
genet
materialbas
test
allow
detect
activ
viremia
contrast
serolog
test
reflect
past
acquisit
infect
import
recipi
diagnosi
also
recognit
donor
infect
retrospect
donor
diagnosi
possibl
appropri
specimen
store
postmortem
recognit
viral
infect
transmit
transplant
increas
like
due
increas
recognit
unexpect
symptom
consist
transmiss
due
increasingli
sophist
diagnost
test
recipi
donor
investig
potenti
donortransmit
infect
requir
rapid
commun
among
physician
transplant
center
organ
procur
organ
public
health
author
immedi
system
track
dissemin
pertin
patient
data
evalu
donorderiv
infect
associ
advers
event
outcom
need
system
establish
clinician
report
unexpect
outcom
unexplain
ill
transplant
recipi
local
organ
tissu
procur
organ
given
frequenc
latent
viral
infect
notabl
among
herpesvirus
reactiv
latent
infect
provid
major
sourc
infect
transplant
specif
viru
tissu
infect
stimuli
activ
natur
host
immun
respons
impact
natur
viral
latenc
virus
metabol
inact
latent
other
continu
replic
low
level
may
determin
effect
host
immun
respons
multipl
factor
contribut
viral
reactiv
transplant
includ
graft
reject
therapi
immun
suppress
especi
reduct
tcell
mediat
cytotox
immun
inflamm
tissu
injuri
numer
cellular
pathway
involv
control
viral
replic
activ
transplant
nuclear
factor
kb
ikb
jakstat
janu
famili
protein
tyrosin
kinas
jak
signal
transduc
activ
transcript
stat
protein
antireject
therapi
also
result
signific
releas
proinflammatori
cytokin
may
increas
viral
replic
gener
reactiv
virus
especi
late
transplant
suggest
new
immun
defect
eg
cancer
rel
overimmunosuppress
latenc
reactiv
best
studi
herpesvirus
establish
lifelong
latent
infect
primari
infect
gener
latenc
consid
absenc
viral
replic
viral
genom
present
cell
without
replic
spread
studi
virus
friend
viru
mice
suggest
protect
antivir
immun
activ
process
mediat
leaki
lowlevel
viral
replic
exist
true
latenc
oppos
lowlevel
replic
remain
controversi
herpesvirus
make
latenc
protein
control
viral
persist
within
target
cell
influenc
cellular
process
latent
state
character
low
level
absenc
detect
viral
antigen
minim
transcript
product
lytic
cycl
gene
express
latencyassoci
viral
transcript
viral
latenc
may
occasion
interrupt
lead
reactiv
spread
infecti
viru
without
recurr
diseas
ebv
establish
latenc
b
lymphocyt
associ
express
limit
set
viral
gene
immun
control
hsv
infect
replic
occur
level
skin
mucosa
initi
recurr
infect
dorsal
root
ganglion
latenc
reactiv
control
immun
mechan
mediat
interferon
myeloid
plasmacytoid
dendrit
cell
cell
cytokin
despit
similar
molecular
detail
mechan
latenc
reactiv
vari
consider
among
herpesvirus
mechan
respons
mainten
latenc
unclear
reactiv
cmv
extens
studi
cmv
viral
genom
found
monocyt
progenitor
cell
although
primari
reservoir
latent
cmv
mechan
latenc
maintain
unknown
allogen
immun
respons
fever
via
tumor
necrosi
factora
tnfa
shown
vitro
increas
cmv
promot
activ
viral
replic
immun
suppress
essenti
reactiv
latent
cmv
serv
perpetu
infect
activ
subclin
activ
cmv
common
increas
diagnos
sensit
molecular
assay
virus
bk
polyomaviru
specif
type
tissu
damag
warm
ischemia
reperfus
injuri
may
precipit
viral
activ
link
inflammatori
state
graft
via
activ
tnfa
nuclear
factor
kappa
b
nfkb
neutrophil
infiltr
nitric
oxid
synthesi
tubularcel
injuri
enhanc
express
cellsurfac
molecul
may
contribut
viral
activ
thu
immun
injuri
inflammatori
cytokin
ischemiareperfus
injuri
stimul
viral
replic
chang
express
virusspecif
cellsurfac
receptor
host
direct
pathway
antivir
cellular
immun
respons
within
allograft
less
effect
due
mismatch
major
histocompat
antigen
organ
donor
host
depend
indirect
pathway
antigen
present
factor
may
render
allograft
suscept
viral
infect
common
reactiv
infect
transplant
includ
cmv
hbv
hcv
hiv
hpv
vzv
zoster
less
clinic
common
viral
infect
relat
reactiv
includ
polyoma
virus
bk
jc
human
herp
viru
human
herp
viru
reactiv
one
viru
may
lead
reactiv
other
multipl
studi
shown
infect
andor
risk
factor
cmv
diseas
cmv
infect
may
trigger
reactiv
reactiv
infect
routin
caus
signific
clinic
diseas
cmv
hsv
vzv
other
may
caus
variabl
ill
exampl
commonli
reactiv
immunosuppress
especi
hsct
often
clinic
signific
infect
contrast
role
sot
recipi
less
well
defin
reactiv
common
clinic
diseas
gener
evid
base
epidemiolog
exposur
new
infect
environ
commonli
acquir
transplant
respiratori
virus
common
new
infect
transplant
includ
rsv
influenza
parainfluenza
adenoviru
new
respiratori
pathogen
metapneumoviru
sar
coronaviru
also
caus
major
infect
immunocompromis
host
gastrointestin
virus
rotaviru
norwalk
viru
common
caus
signific
diarrhea
dehydr
diarrheal
syndrom
may
alter
absorb
calcineurin
inhibitor
eg
cyclosporin
tacrolimu
unexpectedli
elev
level
tacrolimu
nonimmun
patient
acquir
primari
ebv
cmv
vzv
parvoviru
infect
posttransplant
period
absenc
previou
immun
attenu
immun
due
immunosuppress
regimen
new
infect
often
sever
prolong
gener
popul
exampl
parvoviru
infect
often
persist
relaps
transplant
patient
occasion
complic
unusu
find
hepat
myocard
pneumon
glomerulopathi
arthriti
transplant
graft
dysfunct
effect
viral
infect
conceptu
direct
indirect
see
tabl
classif
serv
separ
tissueinvas
viral
infect
cellular
tissu
injuri
effect
mediat
inflammatori
respons
eg
cytokin
alter
host
immun
respons
syndrom
fever
neutropenia
eg
cmv
infect
invas
diseas
result
pneumonia
enter
mening
enceph
consid
direct
effect
indirect
effect
viral
infect
gener
thought
immunomodulatori
respons
viral
infect
mediat
cytokin
chemokin
andor
growth
factor
impact
effect
divers
includ
system
immun
suppr
tabl
direct
indirect
effect
cmv
infect
fever
neutropenia
syndrom
leukopenia
fever
myalgia
fatigu
thrombocytopenia
hepat
nephriti
increas
risk
graft
reject
pneumonia
increas
risk
ptld
gastrointestin
invas
coliti
gastriti
ulcer
bleed
perfor
may
increas
risk
infect
hepat
pancreat
chorioretin
sion
predispos
opportunist
infect
notabl
cmv
hcv
infect
addit
viral
infect
may
alter
express
cellsurfac
antigen
eg
major
histocompat
antigen
provok
graft
reject
andor
caus
disregul
cellular
prolifer
contribut
atherogenesi
cardiac
allograft
oblit
bronchiol
lung
transplant
oncogenesi
increas
viral
replic
persist
may
contribut
allograft
injuri
fibrosi
chronic
reject
infect
one
viru
may
stimul
replic
virus
form
viral
cross
talk
note
infect
andor
serv
risk
factor
cmv
diseas
vice
versa
direct
indirect
effect
reactiv
signific
infect
associ
high
level
tnfa
pediatr
renal
bone
marrow
transplant
reactiv
strongli
associ
acut
reject
coinfect
hcv
cmv
predict
acceler
cours
hepat
coinfect
cmv
ebv
increas
risk
posttransplant
lymphoprolif
disord
ptld
theoret
concern
tcell
respons
viral
infect
thought
produc
crossreact
immun
respons
graft
antigen
possibl
via
altern
recognit
within
tcell
receptor
crossreact
term
heterolog
immun
may
provok
abrog
graft
toler
hhv
famili
eight
human
member
caus
signific
diseas
transplant
recipi
risk
mani
infect
reduc
use
valganciclovir
acyclovir
transplant
usual
caus
oral
genit
ulcer
although
may
occur
unexpect
area
well
recurr
diseas
problemat
patient
warrant
consider
secondari
prophylaxi
antivir
therapi
vzv
common
incid
herp
zoster
among
patient
sot
liver
renal
lung
heart
median
time
onset
month
report
razon
et
al
allogen
hsct
one
studi
koc
et
al
develop
vzv
reactiv
median
day
rang
day
posttransplant
primari
dissemin
vzv
infect
lethal
popul
nonimmun
transplant
patient
monitor
care
exposur
clinic
varicella
use
antivir
therapi
varicella
immunoglobulin
prophylaxi
consid
ebv
caus
febril
system
ill
lymphocytosi
leukopenia
hepat
mediat
posttransplant
lymphoprolif
diseas
ptld
ptld
constitut
spectrum
diseas
often
respons
reduc
immunosuppress
previous
immun
host
ebvseroneg
individu
primari
infect
transplant
increas
risk
ebvmedi
ptld
clinic
present
cmv
rang
cmv
syndrom
includ
fever
malais
leukopenia
flulik
ill
myalgia
fatigu
signific
endorgan
diseas
pneumon
coliti
enceph
hepat
chorioretin
cmv
singl
import
pathogen
transplant
recipi
due
direct
indirect
effect
see
commonli
reactiv
transplant
especi
hsctwhere
associ
hepat
pneumon
cmv
reactiv
bone
marrow
suppress
enceph
caus
less
symptomat
clinic
infect
sot
although
indirect
effect
reactiv
studi
commonli
reactiv
transplant
clinic
symptom
caus
uncertain
although
neurolog
symptom
seem
signific
especi
children
caus
kaposi
sarcoma
seen
sot
recipi
rate
higher
gener
popul
preval
depend
patient
donor
countri
origin
hepat
b
c
among
common
indic
liver
transplant
complic
transplant
well
hepat
c
current
common
indic
liver
transplant
account
case
recent
time
recurr
posttransplant
hepat
c
infect
pose
conundrum
treat
hepat
c
reduc
immunosuppress
without
precipit
reject
given
risk
precipit
graft
dysfunct
hepat
c
treatment
interferon
ribavirin
often
defer
extrahepat
transplant
recipi
hepat
b
goal
complet
viral
suppress
transplant
use
hepat
b
immunoglobulin
well
antivir
agent
lowerdos
immunosuppress
time
unclear
antivir
immunosuppress
regimen
optim
popul
liver
transplant
hbv
combin
viral
prophylaxi
hepat
b
immunoglobulin
result
surviv
rate
equival
indic
liver
transplant
respiratori
virus
common
communityacquir
infect
transplant
recipi
given
increas
rate
pneumonia
bacteri
fungal
superinfect
prevent
vaccin
avoid
sick
individu
essenti
diagnosi
respiratori
virus
within
hour
via
enzymelink
immunosorb
assay
elisa
immunofluoresc
stain
avail
medic
center
viral
cultur
time
consum
expens
respiratori
syncyti
viru
parainfluenza
common
communityacquir
respiratori
virus
follow
influenza
adenoviru
antivir
medic
rimantidin
amantidin
oseltamivir
may
prevent
reduc
sever
ill
use
ribavirin
rsv
immun
globulin
adult
prevent
rsv
infect
unproven
ribavirin
commonli
use
document
rsv
infect
lower
respiratori
tract
metapneumoviru
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
emerg
pathogen
transplant
patient
clinic
spectrum
diseas
metapneumoviru
rang
symptomat
even
fatal
asymptomat
case
group
suggest
possibl
correl
graft
reject
lung
transplant
recipi
diagnosi
often
made
use
molecular
assay
full
impact
infect
transplant
yet
realiz
sar
caus
zoonot
coronavirus
highli
contagi
rapidli
progress
form
viral
pneumonia
spread
asia
mani
part
world
earli
number
transplant
patient
infect
die
impact
sar
result
infect
control
issu
signific
activ
organ
transplant
ie
concern
transmit
donorderiv
infect
well
routin
followup
care
transplant
patient
defer
healthcar
visit
gastrointestin
virus
rotaviru
norwalk
viru
may
caus
signific
diarrhea
dehydr
enterovir
infect
summer
month
northern
hemispher
common
complic
prolong
cours
renal
transplant
recipi
bk
viru
associ
rang
clinic
syndrom
immunocompromis
host
viruria
viremia
ureter
ulcer
stenosi
hemorrhag
cystiti
major
patient
bk
viru
infect
asymptomat
infect
jc
polyomaviru
observ
renal
allograft
recipi
nephropathi
associ
bk
viru
alon
andor
progress
multifoc
encephalopathi
pml
jcv
establish
renal
latenc
receptor
present
multipl
tissu
includ
brain
infect
central
nervou
system
gener
present
focal
neurolog
deficit
seizur
may
progress
death
follow
extens
demyelin
human
papilloma
viru
hpv
infect
caus
signific
diseas
renal
transplant
recipi
includ
oral
skin
genit
rectal
lesion
rang
wart
dysplasia
malign
especi
squamou
cell
carcinoma
recent
arriv
vaccin
genit
hpv
infect
may
help
reduc
infect
transplant
recipi
parvoviru
infect
caus
erythropoietinresist
anemia
pancytopenia
myocard
pneumon
direct
renal
involv
glomerulopathi
allograft
dysfunct
report
renal
transplant
recipi
clinic
virolog
respons
treatment
intraven
immunoglobulin
usual
excel
sever
zoonot
virus
caus
major
ill
death
transplant
set
includ
wnv
rabi
lymphocyt
choriomening
viru
lcmv
recent
report
donorderiv
infect
relat
sot
clinic
subtl
infect
donor
often
deadli
infect
recipi
wnv
morbid
sot
risk
meningoenceph
sot
patient
infect
wnv
estim
compar
normal
host
donor
endem
area
screen
wnv
preval
high
asid
donorderiv
infect
rabi
lcmv
report
although
hivinfect
patient
live
longer
die
less
often
complic
relat
acquir
immunodefici
syndrom
aid
experienc
signific
morbid
mortal
relat
endstag
liver
renal
diseas
preliminari
studi
suggest
patient
graft
surviv
similar
hivneg
hivposit
kidney
liver
transplant
recipi
howev
hcv
infect
appear
acceler
even
control
hiv
infect
ongo
multicent
trial
transplant
hiv
infect
continu
drug
interact
immunosuppress
regimen
antiretrovir
drug
necessit
care
monitor
profound
longlast
suppress
tcell
count
patient
receiv
thymoglobulin
induct
therapi
associ
increas
risk
infect
requir
hospit
rapid
sensit
molecular
biologybas
assay
mani
common
virus
transplant
replac
part
serolog
test
vitro
cultur
diagnosi
infect
serolog
assay
gener
less
sensit
transplant
patient
humor
immun
respons
may
delay
absent
one
seri
patient
parvoviru
infect
shown
pcr
assay
neg
igm
assay
quantit
molecular
test
allow
optim
individu
antivir
therapi
prevent
treatment
infect
advanc
signific
manag
cmv
ebv
hepat
b
hepat
c
virus
quantit
assay
viral
load
antigenemia
test
guid
antivir
therapi
nonquantit
ie
qualit
assay
less
use
manag
assess
respons
therapi
differenti
primari
infect
reactiv
reinfect
exampl
chromosom
integr
latent
dna
happen
immunocompet
subject
lead
high
level
viral
dna
whether
infect
activ
one
group
conclud
diagnosi
enceph
made
without
first
exclud
chromosom
integr
measur
dna
load
csf
serum
andor
whole
blood
latent
infect
due
ebvand
cmv
may
qualit
posit
pcr
confirm
need
quantit
assay
blood
test
may
alway
accur
reflect
level
endorgan
diseas
thu
may
use
test
specif
affect
tissu
well
blood
regard
histolog
evalu
tissu
use
pathogenspecif
immunohistochemistri
may
augment
system
assay
patient
cmv
coliti
exampl
may
neg
molecular
antigenemia
blood
assay
cmv
addit
patient
may
shed
cmv
secret
without
true
infect
limit
diagnost
capac
posit
cultur
bk
polyomaviru
may
detect
urin
either
cytolog
look
classic
decoy
cell
pcr
detect
blood
provid
window
opportun
reduc
immunosuppress
possibl
advanc
invas
diseas
adenoviru
may
detect
local
infect
cystiti
neg
blood
assay
treatment
viral
infect
renal
transplant
recipi
includ
reduct
immunosuppress
antivir
therapi
diagnosi
treatment
coinfect
cmv
ebv
use
adjunct
therapi
immunoglobulin
coloni
stimul
factor
overal
level
immunosuppress
major
impact
risk
reactiv
latent
infect
abil
clear
infect
reduc
immunosuppress
regimen
activ
viral
infect
major
contribut
toward
clear
infect
although
present
risk
graft
reject
protect
cytotox
immun
virus
gener
tcell
mediat
initi
reduct
antimetabolit
neutropen
calcineurin
inhibitor
merit
consider
contrast
reduct
steroid
dose
acut
phase
febril
ill
may
caus
acut
adren
insuffici
avail
antivir
therapi
acyclovir
ganciclovir
ribavirin
lamivudin
oseltamivir
often
essenti
toxic
agent
cidofovir
foscarnet
ribavirin
may
complic
manag
notabl
face
reduc
renal
function
patient
receiv
calcineurin
inhibitor
part
immunosuppress
regimen
durat
therapi
often
longer
transplant
patient
normal
host
often
reflect
abil
reduc
overal
level
immunosuppress
less
immunosuppress
may
result
shorter
treatment
time
increas
inform
provid
molecular
diagnost
may
allow
direct
treatment
regimen
antivir
therapi
often
use
prophylaxi
posttransplant
period
especi
individu
risk
primari
infect
gener
acyclovir
relat
agent
use
prevent
hsv
vzv
ganciclovir
valganciclovir
prevent
cmv
well
hsv
vzv
rel
advantag
univers
prophylaxi
ie
use
antivir
medic
suscept
patient
period
transplant
monitor
preemptiv
earli
therapi
remain
establish
metaanalys
suggest
univers
prophylaxi
antivir
medic
sot
recipi
reduc
cmv
diseas
cmvassoci
opportunist
infect
graft
reject
mortal
use
recommend
high
risk
individu
cmvposit
recipi
cmvneg
recipi
cmvposit
organ
studi
indic
univers
prophylaxi
preemptiv
therapi
effect
reduc
incid
cmv
diseas
hsct
set
risk
bone
marrow
toxic
valganciclovir
higher
mani
program
choos
use
preemptiv
monitor
therapi
cmv
variou
adjunct
therapi
help
treat
prevent
viral
infect
immunoglobulin
ie
intraven
immun
globulin
ivig
cmv
hbv
hyperimmun
globulin
prepar
plasma
preselect
high
titer
antibodi
cmv
hbv
respect
well
monoclon
antibodi
rsv
help
prevent
treat
viral
infect
like
due
direct
indirect
immunomodulatori
properti
signific
percent
patient
posttransplant
hypogammaglobulinemia
link
increas
mortal
may
benefit
globulin
replet
may
appar
set
activ
infect
well
prophylaxi
immunostimulatori
agent
interferonalpha
use
treat
hepat
c
help
treat
viral
infect
may
perturb
relationship
graft
host
precipit
reject
revers
neutropenia
done
use
coloni
stimul
factor
gcsf
gener
well
toler
sold
organ
transplant
patient
vaccin
given
patient
earli
possibl
cours
organ
failur
well
advanc
transplant
optim
immun
respons
gener
respons
vaccin
like
occur
given
pretransplant
rather
transplant
nonliv
viral
vaccin
hepat
b
hepat
inject
influenza
rabi
hpv
inject
polio
may
given
preand
posttransplant
see
tabl
classif
live
viral
vaccin
attenu
influenza
deliv
nasal
spray
measl
mump
rubella
varicella
varivax
protect
varicella
nonimmun
subject
well
zostavax
protect
zoster
yellow
fever
oral
polio
vaccinia
smallpox
gener
avoid
sot
patient
chronic
immunosuppress
gvhd
may
given
hsct
consider
futur
travel
trip
home
also
consid
pretransplant
period
vaccin
cmv
ebv
rsv
viral
pathogen
investig
see
also
transmiss
spongiform
encephalopathi
